From Verify.Wiki
Jump to: navigation, search
QuickUpload1085 20170605045547.jpg
Type Private
Founded 1989
Headquarters Rennes, Nantes & Mulhouse, France

London, UK Newark, NJ, USA Montreal, QC, Canada

Key people Jean-Marc Gandon, President & CEO
Number of employees 201-500 employees


Biotrial's mission is to provide our sponsors with high-quality pharmacology services, adding value to their projects by working together and meeting all needs throughout the development process.

To ensure this mission, Biotrial advocates controlled extension of its facilities and prides itself in developing long-standing relationships with our sponsors.

With experience gained from over 20 years activity, Biotrial has established flexible and efficient working practices ensuring client satisfaction – workflow tailor-made to keep to deadlines and budget terms as well as rigorous quality control covering every detail.

The active participation of key members of staff in all projects ensures the quality of our services.[1]


  • Non-clinical Pharmacology
  • Early Development & Translational Medicine
  • Patient Studies
  • Oncology
  • Bioanalysis
  • Core Lab
  • Biometrics
  • Regulatory Affairs & Pharmacovigilance

Regulatory Affairs & Pharmacovigilance Experience

  • Submissions to the French Medicines Agency (ANSM) and other Regulatory Agencies in Europe
  • Participation in ANSM working groups and knowledge of ANSM procedures
  • In-depth expertise with the European Clinical Trial Directive

Regulatory Affairs Services

  • Advice in Submission strategy
  • Certified translations of regulatory and clinical documents
  • Preparation and submission of Clinical Trial Application (CTA) documents
  • Preparation of Investigational Medicinal Product Dossier (IMPD)
  • Preparation of Investigator Brochure (IB)
  • Management of potential questions raised by ANSM or other European Authorities
  • Management of substantial amendments

Pharmacovigilance services

  • Eudravigilance management (initial registrations, IMP declaration, SUSAR declarations)
  • Serious Adverse Event (SAE) collection and processing
  • Suspected Unexpected Serious Adverse Reactions (SUSARs) submission to competent authorities and ethics committees
  • Development Safety Update Report (DSUR) or Periodic Safety Update Report (PSUR) writing and submission


  • Regulatory submission
  • Preparation and submission of a CTA in one week
  • Regulatory monitoring
  • Regulatory Consultancy

Top 5 Recent Tweets

March 19, 2018JalrOrg#study of a new #Buprenophine 8mg Sublingual Tablet Formulation Versus a Reference Formulation in Healthy Male and…
March 16, 2018BiotrialBeing your Global Partner in Early Development means successful lab inspections by the @US_FDA, @agesnews,…

Top 5 Recent News Headlines

Top 5 Lifetime Tweets

Top 5 Lifetime News Headlines


Verification history